株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ジペプチジルペプチダーゼ4(DPP-4)阻害剤の世界市場 - 成長、傾向、予測(2019年~2024年)

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 808270
出版日 ページ情報 英文 100 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.83円で換算しております。
ジペプチジルペプチダーゼ4(DPP-4)阻害剤の世界市場 - 成長、傾向、予測(2019年~2024年) Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年03月01日 ページ情報: 英文 100 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界のジペプチジルペプチダーゼ4(DPP-4)阻害剤市場は、2018年に105億米ドルと評価され、2019年から2024年にかけては4%のCAGRで成長することが予測されています。

当レポートでは、世界のジペプチジルペプチダーゼ4(DPP-4)阻害剤市場を調査し、市場の概要、医薬品タイプ・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査結果
  • 前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 成長要因
  • 阻害要因
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場区分

  • 医薬品別
    • ジャヌビア(シタグリプチンリン酸塩水和物)
    • オングリザ (サクサグリプチン)
    • トラゼンタ (リナグリプチン)
    • ヴィピディア/ネシーナ (アログリプチン)
    • ガルヴァス (ビルダグリプチン)
  • 地域別
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第6章 市場区分

  • 1型糖尿病の患者数
  • 2型糖尿病の患者数

第7章 競合情勢

  • 企業プロファイル
    • Merck And Co.
    • AstraZeneca
    • Bristol Myers Squibb
    • Novartis
    • 武田薬品工業
    • Eli Lilly
    • Boehringer Ingelheim
  • 企業シェア分析
    • Merck And Co.
    • AstraZeneca
    • 武田薬品工業
    • Novartis
    • Eli Lilly & Boehringer Ingelheim

第8章 市場機会と将来展望

目次
Product Code: 62931

Market Overview

The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018 and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.

Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.

Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.

Scope of the Report

The DPP-4 inhibitors market is segmented by brands and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.

Key Market Trends - The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period

The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county's reimbursement authority, which concluded that it doesn't provide any additional benefits, compared to the medicines already on the market.

North America Holds the Highest Market Share

The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.

Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.

Competitive Landscape

Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position until 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
      • 5.1.1.1 Januvia (Sitagliptin)
      • 5.1.1.2 Onglyza (Saxagliptin)
      • 5.1.1.3 Tradjenta (Linagliptin)
      • 5.1.1.4 Vipidia/Nesina (Alogliptin)
      • 5.1.1.5 Galvus (Vildagliptin)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2024)
      • 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.1.2 Canada (Value and Volume, 2012-2024)
      • 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
      • 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012-2024)
      • 5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.2 Germany (Value and Volume, 2012-2024)
      • 5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.3 Italy (Value and Volume, 2012-2024)
      • 5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.4 Spain (Value and Volume, 2012-2024)
      • 5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
      • 5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.6 Russia (Value and Volume, 2012-2024)
      • 5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
      • 5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012-2024)
      • 5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.3.2 Brazil (Value and Volume, 2012-2024)
      • 5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
      • 5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012-2024)
      • 5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.2 South Korea (Value and Volume, 2012-2024)
      • 5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.3 China (Value and Volume, 2012-2024)
      • 5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.4 India (Value and Volume, 2012-2024)
      • 5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.5 Australia (Value and Volume, 2012-2024)
      • 5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.6 Vietnam (Value and Volume, 2012-2024)
      • 5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.7 Malaysia (Value and Volume, 2012-2024)
      • 5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.8 Indonesia (Value and Volume, 2012-2024)
      • 5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.9 Philippines (Value and Volume, 2012-2024)
      • 5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.10 Thailand (Value and Volume, 2012-2024)
      • 5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
      • 5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
      • 5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.2 Iran (Value and Volume, 2012-2024)
      • 5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.3 Egypt (Value and Volume, 2012-2024)
      • 5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.4 Oman (Value and Volume, 2012-2024)
      • 5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.5 South Africa (Value and Volume, 2012-2024)
      • 5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
      • 5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
      • 5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Merck And Co.
    • 7.1.2 AstraZeneca
    • 7.1.3 Bristol Myers Squibb
    • 7.1.4 Novartis
    • 7.1.5 Takeda Pharmaceuticals
    • 7.1.6 Eli Lilly
    • 7.1.7 Boehringer Ingelheim
  • 7.2 Company Share Analysis
    • 7.2.1 Merck And Co.
    • 7.2.2 AstraZeneca
    • 7.2.3 Takeda Pharmaceuticals
    • 7.2.4 Novartis
    • 7.2.5 Eli Lilly & Boehringer Ingelheim

8 MARKET OPPORTUNITIES AND FUTURE TRENDS